Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose Escalation Study of MLN4924 in Adults With Melanoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01011530
First received: November 9, 2009
Last updated: July 15, 2013
Last verified: July 2013

November 9, 2009
July 15, 2013
December 2009
May 2012   (final data collection date for primary outcome measure)
Maximum Tolerated Dose (MTD) and inform recommended phase 2 dose of MLN4924 [ Time Frame: Up to 12 months of treatment ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01011530 on ClinicalTrials.gov Archive Site
  • Anti-tumor activities of MLN4924 [ Time Frame: Up to 12 months of treatment ] [ Designated as safety issue: No ]
  • Pharmacodynamic effects of MLN4924 on blood and tumor cells [ Time Frame: Primarily assessed during the first cycle of therapy ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Dose Escalation Study of MLN4924 in Adults With Melanoma
A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma

This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2 dose of MLN4924 as well as evaluate antitumor activity in patients with metastatic melanoma.

Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Melanoma
Drug: MLN4924
Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
Experimental: MLN4924
MLN4924 via IV infusion
Intervention: Drug: MLN4924
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
37
January 2013
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Each patient must meet all of the following criteria to be enrolled in the study:

  • Diagnosis of metastatic melanoma
  • Measurable disease
  • Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse
  • Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse
  • Willing and able to give written informed consent
  • Suitable venous access for study-required blood sampling
  • Appropriate functional status, including the recovery from the effects of prior antineoplastic therapy, and acceptable organ function as described in the protocol

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Major surgery or, serious infections, or infections that required systematic antibiotic therapy within 14 days before the first dose of study drug
  • Systemic antineoplastic or radiation therapy within 14 days or treatment with any investigational products within 21 days before the first dose of study treatment
  • CYP3A inducers within 14 days of study treatment. Moderate and strong CYP3A inhibitors and CYP3A inducers are not permitted during the study
  • No prior history of amiodarone in the 6 months before the first dose of MLN4924
  • Diarrhea that is greater than Grade 1 as outlined in the protocol
  • Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months
  • Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.
  • Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol
  • Other clinical and laboratory assessments that do not meet the criteria specified in the protocol
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01011530
C15005
No
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Not Provided
Study Director: Medical Monitor Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP